Wells Fargo Initiates Coverage On Madrigal Pharmaceuticals with Overweight Rating, Announces Price Target of $685
Benzinga Newsdesk 3 months ago
NewsInitiationAnalyst RatingsPrice Target
Wells Fargo analyst Sadia Rahman initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight rating and announces Price Target of $685.
Wells Fargo analyst Sadia Rahman initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight rating and announces Price Target of $685.